About Aprea Therapeutics, Inc.
https://atrinpharma.comAprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors.
CEO
Oren Gilad
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-02-13 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
AIGH CAPITAL MANAGEMENT LLC
Shares:539.3K
Value:$485.37K
SPHERA FUNDS MANAGEMENT LTD.
Shares:270K
Value:$243K
NANTAHALA CAPITAL MANAGEMENT, LLC
Shares:205.76K
Value:$185.18K
Summary
Showing Top 3 of 29
About Aprea Therapeutics, Inc.
https://atrinpharma.comAprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.85K ▼ | $3.11M ▲ | $-2.97M ▲ | -160.84K% ▼ | $-0.47 ▲ | $-2.97M ▲ |
| Q2-2025 | $118.11K ▼ | $1.59M ▼ | $-3.24M ▲ | -2.74K% ▼ | $-0.53 ▲ | $-3.38M ▲ |
| Q1-2025 | $162.46K ▼ | $1.76M ▲ | $-3.93M ▼ | -2.42K% ▼ | $-0.66 ▼ | $-4.08M ▼ |
| Q4-2024 | $205.82K ▼ | $1.07M ▼ | $-2.89M ▲ | -1.41K% ▼ | $-0.49 ▲ | $-3.22M ▲ |
| Q3-2024 | $354.62K | $1.61M | $-3.78M | -1.07K% | $-0.64 | $-4.09M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $13.72M ▼ | $14.32M ▼ | $2.68M ▼ | $11.64M ▼ |
| Q2-2025 | $16.53M ▼ | $17.31M ▼ | $3.9M ▼ | $13.41M ▼ |
| Q1-2025 | $19.28M ▼ | $20.22M ▼ | $4.67M ▲ | $15.55M ▼ |
| Q4-2024 | $22.85M ▼ | $23.98M ▼ | $4.67M ▼ | $19.31M ▼ |
| Q3-2024 | $26.25M | $26.89M | $4.95M | $21.95M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-2.97M ▲ | $-3.26M ▼ | $0 | $370.69K ▼ | $-2.81M ▼ | $-3.26M ▼ |
| Q2-2025 | $-3.24M ▲ | $-3.13M ▲ | $0 | $384.88K ▲ | $-2.74M ▲ | $-3.13M ▲ |
| Q1-2025 | $-3.93M ▼ | $-3.63M ▼ | $0 | $55.85K ▼ | $-3.57M ▼ | $-3.63M ▼ |
| Q4-2024 | $-2.89M ▲ | $-3.51M ▼ | $0 | $134.41K ▲ | $-3.4M ▼ | $-3.51M ▼ |
| Q3-2024 | $-3.78M | $-2.47M | $0 | $-1.16K | $-2.44M | $-2.47M |
CEO
Oren Gilad
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-02-13 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
AIGH CAPITAL MANAGEMENT LLC
Shares:539.3K
Value:$485.37K
SPHERA FUNDS MANAGEMENT LTD.
Shares:270K
Value:$243K
NANTAHALA CAPITAL MANAGEMENT, LLC
Shares:205.76K
Value:$185.18K
Summary
Showing Top 3 of 29